Other substances

Paritaprevir

A hepatitis C virus protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Paritaprevir is a synthetic acylsulfonamide, which reversibly inhibits the hepatitis C virus (HCV) protease complex (NS3/NS4A). It disrupts viral replication (NCIt). It is used in the treatment of chronic HCV infection (LiverTox).

Paritaprevir on DrugBank
Paritaprevir on PubChem
Paritaprevir on Wikipedia

Marketed as

Mixture products: HOLKIRA PAK; TECHNIVIE; VIEKIRA PAK; VIEKIRA XR; VIEKIRAX

CC1=CN=C(C=N1)C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)OC5=NC6=CC=CC=C6C7=CC=CC=C75)C(=O)NS(=O)(=O)C8CC8

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme 3CLpro Small molecule In silico	in silico	3.82	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Jul/17/2020
In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors nsp13 nsp14 Small molecule In silico	in silico	0.61	Predicted to inhibit both the SARS-CoV-2 Nsp13 helicase and Nsp14 exoribonuclease.	Aug/28/2020
Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study nsp15 Small molecule In silico	in silico	3.22	Predicted to inhibit the SARS-CoV-2 nsp15 (endoribonuclease) protein.	Sep/04/2020
The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp RdRpol Small molecule In silico	in silico	2.80	Predicted to inhibit the SARS-CoV-2 RNA-dependent RNA polymerase.	Dec/02/2020
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents 3CLpro Small molecule Enzyme assay In vitro In silico	in silico; in vitro enzyme assay		Partialy inhibits (IC50 of 73.4 µM; 70% inhibition at 50 µM) the SARS-CoV-2 3C-like protease in vitro.	Jan/20/2021

AI-suggested references

Link	Publication date
COVID-19: la faillite annoncee de l'essai clinique europeen Discovery.	Feb/25/2021
Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase	Apr/20/2020
Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening	Feb/04/2021
Re-Purposing of Hepatitis C Virus FDA Approved Direct Acting Antivirals as Potential SARS-CoV-2 Protease Inhibitors.	Nov/19/2021
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach	Feb/04/2020
Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.	Jan/24/2021
Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.	Mar/30/2021
Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro	Jun/24/2020
Drug repurposing using computational methods to identify therapeutic options for COVID-19	May/30/2020
Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach.	May/18/2021
Ligand-based quantitative structural assessments of SARS-CoV-2 3CLpro inhibitors: An analysis in light of structure-based multi-molecular modeling evidences	Aug/11/2020
A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study	Jul/26/2021
Target-Centered Drug Repurposing Predictions of Human Angiotensin-Converting Enzyme 2 (ACE2) and Transmembrane Protease Serine Subtype 2 (TMPRSS2) Interacting Approved Drugs for Coronavirus Disease 2019 (COVID-19) Treatment through a Drug-Target Interacti	Nov/18/2020
Antivirals virtual screening to SARS-CoV-2 non-structural proteins	May/05/2021
Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study	Oct/11/2021
Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and in silico COVID-19 drug candidate molecules	Apr/19/2022
Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.	Apr/27/2021
Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment	Mar/13/2021

Export (.csv)